Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Royalty Pharma PLC (RPRX)
NASDAQ:RPRX
Royalty Pharma (RPRX) Stock Price & Analysis
673 Followers
RPRX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$25.54 - $35.49
Previous Close$28.16
Volume1.78M
Average Volume (3M)2.71M
Market Cap
$16.66B
Enterprise Value$25.86B
Total Cash (Recent Filing)$495.31M
Total Debt (Recent Filing)$6.14B
Price to Earnings (P/E)11.1
Beta0.71
Next Earnings
May 09, 2024EPS Estimate
$0.99Next Dividend Ex-Date
May 16, 2024Dividend Yield2.9%
Share Statistics
EPS (TTM)2.54
Shares Outstanding597,434,791
10 Day Avg. Volume2,647,469
30 Day Avg. Volume2,709,360
Standard Deviation0.06
R-Squared0.12
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)2.53
Price to Sales (P/S)5.29
Price to Cash Flow (P/CF)5.30
P/FCF Ratio5.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue11.25
Enterprise Value/Gross Profit10.98
Enterprise Value/Ebitda15.19
Forecast
1Y Price Target
$44.00Price Target Upside56.25% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Royalty Pharma News
PremiumCompany Announcements
Royalty Pharma Backs MorphoSys’s Acquisition with Strategic InvestmentBulls Say, Bears Say
Bulls Say
Clinical DevelopmentsPositive clinical trial results and the anticipation of further regulatory updates could serve as significant drivers for the stock's future appreciation.
Financial PerformanceRPRX reported results that surpassed forecasts, highlighting robust financial health and the potential for continued growth.
Stock BuybackThe company's aggressive share repurchase program demonstrates confidence in its valuation and a shareholder-friendly capital allocation policy.
Bears Say
Financial GuidanceFY24 guidance for portfolio receipts is slightly below estimates.
Intellectual PropertyUncertainty on deuterated ivacaftor royalty remains.
Revenue StreamsRoyalty rights on deuterated ivacaftor and switch rates remain to be seen.
---
Ownership Overview
35.31% Insiders
22.86% Mutual Funds
12.54% Other Institutional Investors
29.29% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RPRX FAQ
What was Royalty Pharma PLC’s price range in the past 12 months?
Royalty Pharma PLC lowest stock price was $25.54 and its highest was $35.49 in the past 12 months.
What is Royalty Pharma PLC’s market cap?
Currently, no data Available
When is Royalty Pharma PLC’s upcoming earnings report date?
Royalty Pharma PLC’s upcoming earnings report date is May 09, 2024 which is in 15 days.
How were Royalty Pharma PLC’s earnings last quarter?
Royalty Pharma PLC released its earnings results on Feb 15, 2024. The company reported $1.149 earnings per share for the quarter, beating the consensus estimate of $1.01 by $0.139.
Is Royalty Pharma PLC overvalued?
According to Wall Street analysts Royalty Pharma PLC’s price is currently Undervalued.
Does Royalty Pharma PLC pay dividends?
Royalty Pharma PLC pays a Quarterly dividend of $0.21 which represents an annual dividend yield of 2.9%. See more information on Royalty Pharma PLC dividends here
What is Royalty Pharma PLC’s EPS estimate?
Royalty Pharma PLC’s EPS estimate is $0.99.
How many shares outstanding does Royalty Pharma PLC have?
Royalty Pharma PLC has 446,691,530 shares outstanding.
What happened to Royalty Pharma PLC’s price movement after its last earnings report?
Royalty Pharma PLC reported an EPS of $1.149 in its last earnings report, beating expectations of $1.01. Following the earnings report the stock price went up 3.231%.
Which hedge fund is a major shareholder of Royalty Pharma PLC?
Among the largest hedge funds holding Royalty Pharma PLC’s share is Viking Global Investors LP. It holds Royalty Pharma PLC’s shares valued at 283M.
---
Royalty Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$44.00 (56.25% Upside)
$44.00 (56.25% Upside)
Blogger Sentiment
Bullish
RPRX Sentiment 85%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 1.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▲ 0.7%
Last 30 Days ▲ 0.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-22.37%
12-Months-Change
Fundamentals
Return on Equity
18.68%
Trailing 12-Months
Asset Growth
-2.57%
Trailing 12-Months
Company Description
Royalty Pharma PLC
New York-based Royalty Pharma Plc is a biopharmaceutical company, which is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry.
---
RPRX Company Deck
---
RPRX Earnings Call
Q4 2024
0:00 / 0:00
---
RPRX Revenue Breakdown
93.34% Income from financial royalty assets
6.62% Other royalty income
0.04% Revenue from intangible royalty assets
---
RPRX Stock 12 Months Forecast
Average Price Target
$44.00
▲(56.25% Upside)
Technical Analysis
Ontrak
―
Arrowhead Pharmaceuticals
―
Ultragenyx Pharmaceutical
―
Vertex Pharmaceuticals
―
Best Analysts Covering RPRX
1 Year
1 Year Success Rate
2/10 ratings generated profit
1 Year Average Return
-8.45%
reiterated a buy rating 12 days ago
Copying Geoff Meacham's trades and holding each position for 1 Year would result in 20.00% of your transactions generating a profit, with an average return of -8.45% per trade.
---